Cover Image
市場調查報告書

Errant Gene Therapeutics, LLC:產品平台分析

Errant Gene Therapeutics, LLC - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 257882
出版日期 內容資訊 英文 23 Pages
訂單完成後即時交付
價格
Back to Top
Errant Gene Therapeutics, LLC:產品平台分析 Errant Gene Therapeutics, LLC - Product Pipeline Review - 2015
出版日期: 2015年04月29日 內容資訊: 英文 23 Pages
簡介

Errant Gene Therapeutics, LLC 是開發、製造並提供肌萎縮脊椎側索硬化症、囊狀纖維化症、亨丁頓舞蹈症、鐮狀紅血球性貧血、地中海貧血等致命疾病治療藥的製藥公司。該公司同時利用遺傳基因的染色絲結構之化學調變和遺傳基因療法這二種技術來開發疫苗。

本報告提供Errant Gene Therapeutics, LLC的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關等資訊。

Errant Gene Therapeutics, LLC的基本資料

  • Errant Gene Therapeutics, LLC概要
  • 主要資訊
  • 企業資料

Errant Gene Therapeutics, LLC:R&D概要

  • 主要的治療範圍

Errant Gene Therapeutics, LLC:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Errant Gene Therapeutics, LLC:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Errant Gene Therapeutics, LLC:藥物簡介

  • Thalagen
  • CG-1521
  • Trichostatin A
  • Gene Therapy for Sickle Cell Anemia
  • Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD

Errant Gene Therapeutics, LLC:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Errant Gene Therapeutics, LLC:暫停中的計劃

Errant Gene Therapeutics, LLC:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07024CDB

Summary

Global Markets Direct's, 'Errant Gene Therapeutics, LLC - Product Pipeline Review - 2015', provides an overview of the Errant Gene Therapeutics, LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Errant Gene Therapeutics, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Errant Gene Therapeutics, LLC including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Errant Gene Therapeutics, LLC's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Errant Gene Therapeutics, LLC's pipeline products

Reasons to buy

  • Evaluate Errant Gene Therapeutics, LLC's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Errant Gene Therapeutics, LLC in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Errant Gene Therapeutics, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Errant Gene Therapeutics, LLC and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Errant Gene Therapeutics, LLC
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Errant Gene Therapeutics, LLC and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Errant Gene Therapeutics, LLC Snapshot
    • Errant Gene Therapeutics, LLC Overview
    • Key Information
    • Key Facts
  • Errant Gene Therapeutics, LLC - Research and Development Overview
    • Key Therapeutic Areas
  • Errant Gene Therapeutics, LLC - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Errant Gene Therapeutics, LLC - Pipeline Products Glance
    • Errant Gene Therapeutics, LLC - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Errant Gene Therapeutics, LLC - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Errant Gene Therapeutics, LLC - Drug Profiles
    • Thalagen
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CG-1521
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Trichosic
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Sickle Cell Anemia
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit HDAC for Cystic Fibrosis and COPD
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Errant Gene Therapeutics, LLC - Pipeline Analysis
  • Errant Gene Therapeutics, LLC - Pipeline Products by Target
  • Errant Gene Therapeutics, LLC - Pipeline Products by Route of Administration
  • Errant Gene Therapeutics, LLC - Pipeline Products by Molecule Type
  • Errant Gene Therapeutics, LLC - Pipeline Products by Mechanism of Action
  • Errant Gene Therapeutics, LLC - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Errant Gene Therapeutics, LLC, Key Information
  • Errant Gene Therapeutics, LLC, Key Facts
  • Errant Gene Therapeutics, LLC - Pipeline by Indication, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Stage of Development, 2015
  • Errant Gene Therapeutics, LLC - Monotherapy Products in Pipeline, 2015
  • Errant Gene Therapeutics, LLC - Phase I, 2015
  • Errant Gene Therapeutics, LLC - Preclinical, 2015
  • Errant Gene Therapeutics, LLC - Discovery, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Target, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Route of Administration, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Molecule Type, 2015
  • Errant Gene Therapeutics, LLC - Pipeline Products by Mechanism of Action, 2015
  • Errant Gene Therapeutics, LLC, Other Locations

List of Figures

  • Errant Gene Therapeutics, LLC - Pipeline by Top 10 Indication, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Stage of Development, 2015
  • Errant Gene Therapeutics, LLC - Monotherapy Products in Pipeline, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Top 10 Target, 2015
  • Errant Gene Therapeutics, LLC - Pipeline by Top 10 Molecule Type, 2015
  • Errant Gene Therapeutics, LLC - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top